InvestorsHub Logo
Followers 22
Posts 3670
Boards Moderated 0
Alias Born 07/20/2006

Re: None

Monday, 07/22/2024 2:06:14 PM

Monday, July 22, 2024 2:06:14 PM

Post# of 3029
From BIOWORLD -

Infection
Enanta Pharmaceuticals describes new PL-pro
July 22, 2024

Enanta Pharmaceuticals Inc. has patented compounds acting as nonstructural protein 3 (nsp3, PL-pro; SARS-CoV-2) inhibitors reported to be useful for the treatment of asthma, SARS-CoV-2 infection (COVID-19), rhinovirus, norovirus and lung infections. [Subscription needed]

https://www.bioworld.com/articles/710689-enanta-pharmaceuticals-describes-new-pl-pro?v=preview
Bullish
Bullish
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent ENTA News